mFOLFOX6+bevacizumab + PD-1 monoclonal antibody in locally advanced MSS CRC (BASKETII): A prospective, single-arm, open-label, phase II study

被引：0
|
作者：
Huang, J. [1 ]
He, W. [2 ]
Zhao, Y. [3 ]
He, F. [4 ]
Liu, Z. [5 ]
Pei, F. [6 ]
Yao, Q. [7 ]
机构：
[1] Sun Yat Sen Univ, Affiliated Hosp 6, Colorectal Surg, Guangzhou, Peoples R China
[2] Jinan Univ, Shenzhen Peoples Hosp, Oncol Dept, Shenzhen, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Pathol, Guangzhou, Peoples R China
[4] Sun Yat Sen Univ, Affiliated Hosp 6, Radiotherapy, Guangzhou, Peoples R China
[5] Sun Yat Sen Univ, Affiliated Hosp 6, Coloproctol, Guangzhou, Peoples R China
[6] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou, Peoples R China
[7] Sun Yat Sen Univ, Affiliated Hosp 6, Guangzhou, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.1016/j.annonc.2024.10.096
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
74MO
引用
收藏
页码：S1433 / S1433
页数：1
相关论文
共 50 条
  • [41] Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
    Chen, Jie
    Li, Chen
    Cao, Yuanjie
    Zhu, Li
    Zhang, Bailin
    You, Jinqiang
    Hou, Hailing
    Wang, Jing
    Yuan, Zhiyong
    BMC CANCER, 2022, 22 (01)
  • [42] Toripalimab combined with concurrent platinum-based Chemoradiotherapy in patients with locally advanced cervical Cancer: an open-label, single-arm, phase II trial
    Jie Chen
    Chen Li
    Yuanjie Cao
    Li Zhu
    Bailin Zhang
    Jinqiang You
    Hailing Hou
    Jing Wang
    Zhiyong Yuan
    BMC Cancer, 22
  • [43] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Yanshuo Cao
    Ming Lu
    Yu Sun
    Jifang Gong
    Jie Li
    Zhihao Lu
    Jian Li
    Xiaotian Zhang
    Yan Li
    Zhi Peng
    Jun Zhou
    Xicheng Wang
    Lin Shen
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 779 - 789
  • [44] Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial
    Guo, Honghai
    Ding, Ping'an
    Sun, Chenyu
    Yang, Peigang
    Tian, Yuan
    Liu, Yang
    Lowe, Scott
    Bentley, Rachel
    Li, Yaru
    Zhang, Zhidong
    Wang, Dong
    Li, Yong
    Zhao, Qun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [45] HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
    Lin, Shi-Ming
    Lu, Sheng-Nan
    Chen, Ping-Tsung
    Jeng, Long-Bin
    Chen, Shinn-Cherng
    Hu, Chi-Tan
    Yang, Sien-Sing
    Le Berre, Marie-Aude
    Liu, Xuan
    Mitchell, David Y.
    Prins, Klaas
    Grevel, Joachim
    Pena, Carol A. E.
    Meinhardt, Gerold
    HEPATOLOGY INTERNATIONAL, 2017, 11 (02) : 199 - 208
  • [46] HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma
    Shi-Ming Lin
    Sheng-Nan Lu
    Ping-Tsung Chen
    Long-Bin Jeng
    Shinn-Cherng Chen
    Chi-Tan Hu
    Sien-Sing Yang
    Marie-Aude Le Berre
    Xuan Liu
    David Y. Mitchell
    Klaas Prins
    Joachim Grevel
    Carol A. E. Peña
    Gerold Meinhardt
    Hepatology International, 2017, 11 : 199 - 208
  • [47] Neoadjuvant tislelizumab with afatinib for locally advanced head and neck squamous cell carcinoma (neoCHANCE-1): An open-label, single-arm, phase 2 study
    Wei, Zhigong
    Chen, Huijiao
    Cai, Lei
    Chen, Fei
    Liu, Jun
    Peng, Xingchen
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [48] Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
    Ma, Xinran
    Li, Ling
    Zhang, Lei
    Fu, Xiaorui
    Li, Xin
    Wang, Xinhua
    Wu, Jingjing
    Sun, Zhenchang
    Zhang, Xudong
    Feng, Xiaoyan
    Chang, Yu
    Zhou, Zhiyuan
    Nan, Feifei
    Zhang, Jieming
    Li, Zhaoming
    Zhang, Mingzhi
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 : 275 - 284
  • [49] Apatinib plus camrelizumab in patients with advanced cervical cancer: A multicentre, open-label, single-arm, phase II trial
    Huang, X.
    Shen, J.
    Xiong, Y.
    Wang, Y.
    Cao, X.
    He, M.
    Zou, G.
    Deng, Y.
    Wang, X.
    Lan, C.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 43 - 43
  • [50] A single-arm, open-label, phase II study of tislelizumab combined with lenvatinib and Gemox regimen for conversion therapy of potentially resectable locally advanced biliary tract cancers
    Li, H.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S570 - S570
12345